Although I am happy no TO has come, Yes I find it odd that to date no TO offer given the excellence of our leading drug and now perhaps second is indicating.
Leads me to think naturally there have been discussions but nothing the board is ready for yet.
This failure of our competitor just boosted our future sales, leaving Daybue the 1st and only treatment for Rhetts, staggering the market hasn't marked us up $5 minimum.....
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-114
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.62 |
Change
-0.240(1.15%) |
Mkt cap ! $2.635B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $20.62 | $20.26 | $4.698M | 229.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 221 | $20.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.62 | 1553 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |